Different Metabolic Characteristics in the Presence of Brown Adipose Tissue in Humans

This study has been completed.
Information provided by (Responsible Party):
K. M. Choi, Korea University
ClinicalTrials.gov Identifier:
First received: August 24, 2011
Last updated: March 16, 2015
Last verified: September 2011
Functional brown adipose tissue (BAT) exists in adult humans and can be detected by PET and especially during acute cold exposure. It is conceivable that BAT activity might reduce the risk of developing obesity since fat stores are used for thermogenesis, and a directed enhancement of adipocyte metabolism might have value in weight reduction. So it is important to know the different metabolic characteristics in human adults who have detected BAT. Therefore, the purpose of the investigators study is to compare different metabolic characteristics in the presence of brown adipose tissue in humans.

Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Different Metabolic Characteristics in the Presence of Brown Adipose Tissue in Humans

Resource links provided by NLM:

Further study details as provided by Korea University:

Primary Outcome Measures:
  • presence metabolic syndrome [ Time Frame: 5 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • BMI [ Time Frame: 5 months ] [ Designated as safety issue: No ]
  • visceral fat area [ Time Frame: 5 months ] [ Designated as safety issue: No ]
  • adipokines [ Time Frame: 5 months ] [ Designated as safety issue: No ]
  • sarcopenia [ Time Frame: 5 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
plasma and serum

Enrollment: 90
Study Start Date: December 2010
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
brown adipose tissue detected, undetected


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients who underwent 18FDG-PET/CT scan year between 2008-2010.

Inclusion Criteria:

  • Patients who underwent 18FDG-PET/CT scan year between 2008-2010

Exclusion Criteria:

  • History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
  • Diabetes
  • Stage 2 hypertension
  • Severe renal or hepatic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01430338

Korea, Republic of
korea University Guro Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University
  More Information

Responsible Party: K. M. Choi, Professor, Korea University
ClinicalTrials.gov Identifier: NCT01430338     History of Changes
Other Study ID Numbers: BAT 
Study First Received: August 24, 2011
Last Updated: March 16, 2015
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Metabolic Syndrome X
Glucose Metabolism Disorders
Insulin Resistance
Metabolic Diseases

ClinicalTrials.gov processed this record on May 30, 2016